Literature DB >> 23301385

Comparison of two commercially available methods for HPV genotyping: CLART HPV2 and Linear Array HPV Genotyping tests.

Aikaterini Chranioti1, Aris Spathis, Evangelia Aga, Christos Meristoudis, Asimakis Pappas, Ioannis Panayiotides, Petros Karakitsos.   

Abstract

OBJECTIVE: To compare the clinical efficiency of two commercially available HPV DNA detection and typing tests. The CLART HPV2 test, a novel HPV test based on DNA microarrays that can identify 35 HPV genotypes, was compared to the Linear Array HPV Genotyping (LA) test, a more widely used test able to identify 37 HPV genotypes. STUDY
DESIGN: The CLART test was evaluated by comparing the genotyping results of 538 ThinPrep Pap tests with the LA test as well as with the cytological and histological findings.
RESULTS: The exact same types and results were identified in 86.1% of the samples (kappa = 0.74). The tests showed excellent agreement in HPV positivity and identification of single and multiple infections (concordance rate 88.7%, kappa = 0.827).
CONCLUSION: The CLART test demonstrated results comparable to those of the LA test in clinical sensitivity as measured by the positive predictive value of CIN2+ in ASCUS (67.3% vs. 57.1%), while overall it exhibited higher sensitivity, specificity, positive and negative predictive values and area under curves than the LA test in all cytological and histological subgroups analyzed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23301385

Source DB:  PubMed          Journal:  Anal Quant Cytopathol Histpathol        ISSN: 2578-742X


  5 in total

1.  HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system.

Authors:  Jesper Bonde; Matejka Rebolj; Ditte Møller Ejegod; Sarah Preisler; Elsebeth Lynge; Carsten Rygaard
Journal:  BMC Infect Dis       Date:  2014-07-26       Impact factor: 3.090

2.  Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.

Authors:  Ditte Møller Ejegod; Matejka Rebolj; Jesper Bonde
Journal:  BMC Cancer       Date:  2015-04-02       Impact factor: 4.430

3.  Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.

Authors:  Edward Kumakech; Vanja Berggren; Henry Wabinga; Gabriella Lillsunde-Larsson; Gisela Helenius; Malin Kaliff; Mats Karlsson; Samuel Kirimunda; Caroline Musubika; Sören Andersson
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

4.  Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays.

Authors:  Matejka Rebolj; Jesper Bonde; Sarah Preisler; Ditte Ejegod; Carsten Rygaard; Elsebeth Lynge
Journal:  J Clin Microbiol       Date:  2016-08-17       Impact factor: 5.948

5.  Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.

Authors:  Sarah Preisler; Matejka Rebolj; Ditte Møller Ejegod; Elsebeth Lynge; Carsten Rygaard; Jesper Bonde
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.